Susquehanna International Group’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $292K | Buy |
+12,900
| New | +$287K | ﹤0.01% | 10921 |
|
|
2025
Q1 | – | Sell |
-17,600
| Closed | -$332K | – | 13207 |
|
|
2024
Q4 | $332K | Sell |
17,600
-69,000
| -80% | -$1.21M | ﹤0.01% | 9601 |
|
|
2024
Q3 | $1.3M | Sell |
86,600
-45,500
| -34% | -$778K | ﹤0.01% | 6223 |
|
|
2024
Q2 | $3.78M | Buy |
132,100
+93,900
| +246% | +$2.67M | ﹤0.01% | 3898 |
|
|
2024
Q1 | $1.12M | Buy |
38,200
+900
| +2% | +$27.6K | ﹤0.01% | 6629 |
|
|
2023
Q4 | $1.26M | Sell |
37,300
-23,400
| -39% | -$685K | ﹤0.01% | 6419 |
|
|
2023
Q3 | $1.86M | Sell |
60,700
-45,100
| -43% | -$1.63M | ﹤0.01% | 5276 |
|
|
2023
Q2 | $4.24M | Buy |
105,800
+44,700
| +73% | +$1.85M | ﹤0.01% | 3788 |
|
|
2023
Q1 | $2.49M | Buy |
+61,100
| New | +$2.43M | ﹤0.01% | 4695 |
|
|
2022
Q4 | – | Sell |
-22,400
| Closed | -$1.19M | – | 13348 |
|
|
2022
Q3 | $1.19M | Buy |
22,400
+16,200
| +261% | +$901K | ﹤0.01% | 6183 |
|
|
2022
Q2 | $361K | Sell |
6,200
-52,800
| -89% | -$3.46M | ﹤0.01% | 9053 |
|
|
2022
Q1 | $4.5M | Buy |
59,000
+32,600
| +123% | +$2.17M | ﹤0.01% | 3812 |
|
|
2021
Q4 | $1.59M | Buy |
26,400
+12,500
| +90% | +$689K | ﹤0.01% | 6074 |
|
|
2021
Q3 | $778K | Sell |
13,900
-2,900
| -17% | -$167K | ﹤0.01% | 8209 |
|
|
2021
Q2 | $1.02M | Sell |
16,800
-700
| -4% | -$44.3K | ﹤0.01% | 7708 |
|
|
2021
Q1 | $1.23M | Sell |
17,500
-15,300
| -47% | -$1.09M | ﹤0.01% | 7184 |
|
|
2020
Q4 | $1.96M | Sell |
32,800
-10,000
| -23% | -$586K | ﹤0.01% | 5143 |
|
|
2020
Q3 | $2.57M | Buy |
42,800
+17,000
| +66% | +$988K | ﹤0.01% | 4138 |
|
|
2020
Q2 | $1.35M | Sell |
25,800
-25,700
| -50% | -$1.07M | ﹤0.01% | 5233 |
|
|
2020
Q1 | $1.73M | Buy |
51,500
+21,100
| +69% | +$877K | ﹤0.01% | 4232 |
|
|
2019
Q4 | $1.38M | Sell |
30,400
-1,100
| -3% | -$46.7K | ﹤0.01% | 4942 |
|
|
2019
Q3 | $1.2M | Sell |
31,500
-35,900
| -53% | -$1.43M | ﹤0.01% | 5301 |
|
|
2019
Q2 | $2.93M | Buy |
67,400
+15,200
| +29% | +$645K | ﹤0.01% | 3486 |
|
|
2019
Q1 | $1.99M | Buy |
52,200
+14,500
| +38% | +$566K | ﹤0.01% | 3755 |
|
|
2018
Q4 | $1.62M | Sell |
37,700
-47,800
| -56% | -$2.23M | ﹤0.01% | 3838 |
|
|
2018
Q3 | $4.2M | Sell |
85,500
-12,700
| -13% | -$549K | ﹤0.01% | 2885 |
|
|
2018
Q2 | $3.15M | Sell |
98,200
-3,400
| -3% | -$117K | ﹤0.01% | 3320 |
|
|
2018
Q1 | $3.17M | Sell |
101,600
-9,000
| -8% | -$320K | ﹤0.01% | 3176 |
|
|
2017
Q4 | $5.05M | Buy |
110,600
+26,900
| +32% | +$1.07M | ﹤0.01% | 2527 |
|
|
2017
Q3 | $3.14M | Buy |
83,700
+45,000
| +116% | +$1.81M | ﹤0.01% | 3163 |
|
|
2017
Q2 | $1.85M | Sell |
38,700
-72,700
| -65% | -$3.37M | ﹤0.01% | 4049 |
|
|
2017
Q1 | $5.08M | Sell |
111,400
-215,100
| -66% | -$9.3M | ﹤0.01% | 2338 |
|
|
2016
Q4 | $10.5M | Buy |
326,500
+63,100
| +24% | +$2.11M | 0.01% | 1516 |
|
|
2016
Q3 | $9.01M | Buy |
263,400
+122,700
| +87% | +$4.81M | ﹤0.01% | 1606 |
|
|
2016
Q2 | $4.75M | Sell |
140,700
-8,800
| -6% | -$432K | ﹤0.01% | 2271 |
|
|
2016
Q1 | $7.92M | Sell |
149,500
-22,800
| -13% | -$1.33M | ﹤0.01% | 1786 |
|
|
2015
Q4 | $13.2M | Buy |
172,300
+98,500
| +133% | +$5.58M | 0.01% | 1508 |
|
|
2015
Q3 | $3.03M | Sell |
73,800
-113,700
| -61% | -$6.96M | ﹤0.01% | 3479 |
|
|
2015
Q2 | $13.3M | Sell |
187,500
-2,900
| -2% | -$228K | 0.01% | 1691 |
|
|
2015
Q1 | $16.9M | Buy |
190,400
+112,600
| +145% | +$11.4M | 0.01% | 1378 |
|
|
2014
Q4 | $6.9M | Sell |
77,800
-37,200
| -32% | -$3.52M | ﹤0.01% | 2438 |
|
|
2014
Q3 | $11.1M | Buy |
115,000
+32,800
| +40% | +$3.19M | ﹤0.01% | 1994 |
|
|
2014
Q2 | $7.55M | Buy |
82,200
+40,000
| +95% | +$3.05M | ﹤0.01% | 2466 |
|
|
2014
Q1 | $2.95M | Buy |
42,200
+10,000
| +31% | +$680K | ﹤0.01% | 3677 |
|
|
2013
Q4 | $1.85M | Buy |
32,200
+8,900
| +38% | +$468K | ﹤0.01% | 4414 |
|
|
2013
Q3 | $1.12M | Buy |
23,300
+13,500
| +138% | +$492K | ﹤0.01% | 5089 |
|
|
2013
Q2 | $284K | Buy |
+9,800
| New | +$283K | ﹤0.01% | 6890 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Susquehanna International Group's PCRX Position: Q1 2026 in Review
Susquehanna International Group increased its Pacira BioSciences (PCRX) stake by 30% in Q1 2026, buying an estimated $182K and bringing the position to 35,483 shares worth $802K. The position accounts for ﹤0.01% of the portfolio, ranked #8467.
Susquehanna International Group first reported a position in PCRX in Q2 2013 and has held it in 42 quarters since. The position peaked at $8.55M in Q4 2016. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Susquehanna International Group held 35,483 shares of Pacira BioSciences worth $802K as of Q1 2026.
- Susquehanna International Group bought 8,189 Pacira BioSciences shares in Q1 2026, an estimated $182K.
- Pacira BioSciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8467 holding.
- Susquehanna International Group first reported a position in Pacira BioSciences in Q2 2013 and has held it in 42 quarters since.
- Susquehanna International Group's Pacira BioSciences position peaked at $8.55M in Q4 2016.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.